polypeptide cofactor that is evolutionarily conserved from yeast to humans. The protein was so named to re ect its widespread tissue distribution across species.
e UPP employs the concerted actions of a succession of speci c enzymes (E1, E2, and E3) that sequentially conjugate chains of Ub onto proteins that are destined for degradation via a three-step process of Ub activation and substrate recognition. 1 is tagging process, known as ubiquitination, is a prelude to the recognition and nal execution of the protein destruction command by the 26S proteasome.
e 26S proteasome is a large subcellular organelle found in the nucleus and the cytosol of all cells. It constitutes approximately 1 -2 % of cell mass and provides the site for adenosine triphosphate-dependent degradation of Ubtagged proteins. 2 e 26S proteasome is essentially a hollow cylindrical particle made up of a 20S catalytic component and a 19S regulatory unit. e central 20S complex is made up of four heptameric protein rings assembled like four doughnuts comprising two identical outer -rings and two identical inner -rings, each containing seven subunits, 1 -7 and 1 -7, respectively. The 1, 2, Body proteins were once viewed as structurally static, while dietary proteins were believed to function primarily as sources of energy. With the discovery of the lysosome, Greek for ' digestive body, ' more than half a century ago, it had been assumed that cellular proteins were degraded within this organelle until lysosomal inhibitors were found to be ine ective in preventing basal protein breakdown. In the past two decades, the focus in this eld has shi ed to the ubiquitin-proteasome pathway (UPP), a tightly regulated system that degrades intracellular proteins to facilitate cellular adaptations to new physiologic conditions. Indeed, the discovery of ubiquitin and the understanding of its role in protein degradation led to the awarding of the 2004 Nobel Prize in Chemistry to corecipients Avram Hershko, Aaron Ciechanover, and Irwin Rose.
Ubiquitin (Ub) is an abundant 9-kilodalton or 76-amino acid cellular and 5 subunits harbor the active proteolytic sites that are positioned toward the hollow center of the cylinder structure and possess postglutamyl-, trypsin-, and chymotrypsin-like hydrolytic activities, respectively. The two -rings sandwiching the -rings ( 7 -7 -7 -7 arrangement) surround a narrow, central pore for substrate entry and product exit. e 19S complex caps the -ring on each side and acts as a gatekeeper to allow passage only of Ub-tagged proteins into the proteasome, thus preventing nonspeci c destruction of cell proteins ( Figure 1 ).
By virtue of its ability to handle vast amounts of intracellular proteins, the UPP forms an integral component in numerous cellular processes, including cell-cycle regulation, induction of the in ammatory response, and antigen presentation. Not surprisingly, aberrations of the UPP have been implicated in many disease states, including infection, carcinogenesis, uremic muscle wasting, and antibody-mediated autoimmune disorders. 3 Here, we focus on the role of the UPP in immune surveillance and regulation.
Many transcriptional factors undergo ubiquitination followed by proteasomal degradation. One relevant example is the regulation of nuclear factor-B (NF-B) activation. This proinflammatory transcriptional activator is normally secluded outside the cell nucleus through its association with I B. Inflammatory signals activate phosphorylation of I B, which becomes recognized by the E3 -transducin repeat-containing protein, a member of the Ub conjugation enzymatic cascade. I B is then ubiquitinated and rapidly degraded, releasing the NF-B complex that translocates into the nucleus to trigger downstream in ammatory response. 4 Proteasomal breakdown of intracellular proteins enables the immune system to detect foreign proteins through interactions with major histocompatibility complex (MHC) class I molecules that bind oligopeptides that are 8 -10 residues long. Most proteasomal cleavage products are too long and must be trimmed at the N terminus in the endoplasmic reticulum by aminopeptidases a er they are taken up by a speci c peptide transport system, called transporter associated with antigen processing (TAP). Endoplasmic reticulum aminopeptidase 1 (ERAP1) then tailors these peptides to the precise length for binding to MHC class I molecules before they are delivered to the cell surface for presentation to cytotoxic CD8 + lymphocytes. 5 Non-native epitopes presented on the cell surface, such as those derived from viruses or cancerous cells, are recognized by cytotoxic T cells, which rapidly destroy the presenting cell.
To enhance the efficiency of antigen presentation during inflammation, immune cells develop several adaptive mechanisms. Interferon-(IFN-), produced mainly by T-helper 1 ( 1) cells, cytotoxic T cells, dendritic cells, and natural killer cells, is a prominent cytokine featured in many in ammatory conditions. In response to IFN-challenge, immune cells undergo a switch to express novel types of proteasomes, termed immunoproteasomes (iPSs), which play a major role in augmenting the e ciency of MHC class I presentation. 6 e iPSs di er because they contain three novel peptidase subunits, LMP2, MECL-1, and LMP5, that replace their constitutive counterparts 1, 2, and 5, respectively. These specialized peptidases, together with the superinduction of a special proteasome-activating complex, PA28, exhibit enhanced protein cleavage properties that expand the number of products capable of binding to MHC class I molecules and acting as antigenic precursors. In addition, IFN-upregulates the expression of the TAP transporter, the ERAP1 peptidetrimming enzyme, and MHC molecules. Collectively, these adaptive responses elevate host defense to new heights ( Figure 1 ). Mice that lack iPS subunits were unable to e ciently process and present CD8 + T-cell epitopes. Apparently, antigen processing constitutively functions well below maximal levels until activation of the host ' s defenses is necessary. Switching from proteasome to IFN--inducible iPS, therefore, allows more e cient antigen presentation and facilitates recognition of foreign cells and their rapid elimination under a variety of conditions. IgA nephropathy (IgAN) is a disease arising from structural aberrations, such as anomalous galactosylation of the IgA molecule, which becomes trapped in the glomerular mesangium and induces variable degrees of hematuria, proteinuria, and progressive renal failure. 7 e typical exacerbation of hematuria in some patients following a mucosal infection suggests the participation of infectious agents in disease pathogenesis. In agreement with this notion, Coppo et al. 8 (this issue) report a signi cant switch from proteasome to iPS expression, reflected by increased iPS / proteasome catalytic subunit ratios, in peripheral blood mononuclear cells of patients with IgAN. Understandably, this phenotypic switch, along with activation of NF-B p50 and p65 , will augment the e ciency of MHC class I antigen processing and presentation to reactive T cells. More importantly, the authors show that the pattern of this switch was completely di erent from that of control subjects with respiratory or gastrointestinal infections without renal disease, or subjects with idiopathic nephrotic syndrome, highlighting the probable speci city of the proteasomal switch in IgAN. Of the three active catalytic iPS subunits, only LMP7 correlated with proteinuria levels in IgAN, but not in other nephrotic states.
Indeed, participation of the proteasome or its switching to iPS is being increasingly recognized during viral infections. iPSs were induced in hepatocytes during hepatitis C infection. E cient antigen presentation required the structural components of iPSs during hepatitis B infection. 9 During fungal infection, there was a switch of 1 and 5 to their LMP2 and LMP7 counterparts, 10 respectively, whereas in HIV infection, these critical immune processes were attenuated. Infection of mice with lymphocytic choriomeningitis virus or Listeria monocytogenes led to a near-complete replacement of proteasomes by iPSs in the liver. 11 The putative enhancing e ect of iPS switching on T-cell responses, however, was recently challenged by Nussbaum et al. , 12 who demonstrated similar virus-speci c CD8 + T-cell responses and viral clearance rates between wild-type and LMP2 − / − mice .
Given the prominent role of proteasomal switching during various viral infections, Coppo et al. 8 postulated that the iPS upregulation observed in IgAN may re ect a host response to immune challenges, possibly from viral infections that trigger IFN-release. Such a contention is in agreement with the activation of the Th1 lymphocyte subset leading to increased release of IFN-, among other cytokines, in IgAN. 13 ere are, however, certain caveats to their observation. e identity of this infectious agent remains an enigma, and evidence of an infective pathogenetic origin of IgAN as suggested by iPS induction is only circumstantial.
e adaptive signi cance of a switch to only LMP7 and MECL-1, but not LMP2, remains to be explored. If viral infection were indeed a culprit, presumably more than one pathogen would be involved, in view of the diverse nature of IgAN. en, it remains to be explained why only a single pattern of switching was observed, given that di erent pathogens are known to induce di erent iPS subunits . Although correlation with proteinuria is relevant, the reason behind the exclusive participation of LMP7 is as yet unclear. Finally, whether proteasomal switching in peripheral blood mononuclear cells can be extrapolated to B cells that maintain a continuous mucosa-bone marrow crosstalk in IgAN 14 remains to be explored.
Nonetheless, the novel nding of proteasomal switching to iPSs in peripheral blood mononuclear cells in IgAN has shed new light on the pathogenesis of IgAN and provided new evidence for immune activation in IgAN. Further research is necessary to carefully characterize the speci city and signaling mechanisms underlying this phenotypic switch and how this might translate into nephritis. Clinical trials examining the therapeutic potential of proteasome inhibitors lie further away.
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